Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

GenFleet Starts Combo Trial of CDK9 Inhibitor with BeiGene’s BTK Inhibitor

publication date: Mar 28, 2024

Shanghai GenFleet announced a clinical trial collaboration to test a combination of GFH009 (a CDK9 inhibitor) and BioGene’s Brukinsa® (a BTK inhibitor) in patients with diffuse large B cell lymphoma (DLBCL). GenFleet will conduct an open-label, single-arm and multi-center (10 hospitals in China) study of the combination to evaluate its safety and efficacy. BeiGene will provide clinical drug supplies of Brukinsa®(zanubrutinib) for the Phase Ib/II trial. The first patient has been dosed in the trial, which is led by Henan Cancer Hospital and Fudan University Shanghai Cancer Center. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here